Expanding the use of neurotoxins in facial aesthetics: A consensus panel's assessment and recommendations

Journal of Drugs in Dermatology

Volumn 9, Issue 1, 2010, Pages

  Kane, Michael A C ^a   Donofrio, Lisa ^b   Ascher, Benjamin ^a   Hexsel, Doris ^c   Monheit, Gary ^d   Rzany, Berthold ^e   Weiss, Robert ^f  

^a Yale University School of Medicine ^*

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^f JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; COSMETIC; NEUROTOXIN; PLACEBO; ABOBOTULINUMTOXINA; MUSCLE RELAXANT AGENT;

BRUISING; CONFERENCE PAPER; CONSENSUS; CROW FEET; DRUG APPROVAL; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG STORAGE; ESTHETICS; FACE ESTHETICS; GERMANY; GLABELLAR LINE; HUMAN; MULTIPLE CYCLE TREATMENT; PATIENT SATISFACTION; PERIORBITAL HEMATOMA; PRACTICE GUIDELINE; PTOSIS; PUBLICATION; RHINOPHARYNGITIS; SKIN BRUISING; SKIN DISEASE; SWELLING; UNITED STATES; CONSENSUS DEVELOPMENT; CUTANEOUS PARAMETERS; DRUG EFFECT; ESTHETIC SURGERY; FACE; STANDARD;

BEAUTY; BOTULINUM TOXIN TYPE A; COSMETIC TECHNIQUES; FACE; HUMANS; NEUROMUSCULAR AGENTS; NEUROTOXINS; PRACTICE GUIDELINES AS TOPIC; SKIN AGING;

EID: 77957655377     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (61)

1. Carruthers JD, Carruthers JA. Treatment of glabellar frown lines with C. botulinum-A exotoxin. J Dermatol Surg Oncol. 1992;18:17-21.
2. Ascher B, Klap P, Marion MH, Chanteloub F. Botulinum toxin in the treatment of frontoglabellar and periorbital wrinkles. An initial study. Ann Chir Plast Esthet. 1995;40:67-76.
3. Kane MA. The functional anatomy of the lower face as it applies to rejuvenation via chemodenervation. Facial Plast Surg. 2005;21:55-64. (Pubitemid 40868931)
4. American Society for Aesthetic Plastic Surgery. 2007 statistics. Available at: http://www.surgery.org/download/2007stats.pdf. Accessed March 13, 2009.
5. Botox Cosmetic (onabotulinumtoxinA) [package insert]. Irvine, California: Allergan, Inc.; July 2009.
6. Dayan SH, Maas CS. Botulinum toxins for facial wrinkles: Beyond glabellar lines. Facial Plast Surg Clin North Am. 2007;15:41-49.
7. Kane MA. Nonsurgical treatment of platysma bands with injection of botulinum toxin A. Plast Reconstr Surg. 1999;103:656-663.
8. Kane MA. The effect of botulinum toxin injections on the nasolabial fold. Plast Reconstr Surg. 2003;112(5 Suppl):66S-72S.
9. Liew S, Dart A. Nonsurgical reshaping of the lower face. Aesthet Surg J. 2008;28:251-257. (Pubitemid 351672087)
10. Ascher B, Rzany BJ, Grover R. Efficacy and safety of botulinum toxin type A in the treatment of lateral crow's feet: Doubleblind, placebo-controlled, dose-ranging study. Dermatol Surg. 2009;5:1478-86.
11. Rzany B. Bericht zum 1. Expertentreffen zur Anwendung von Botulinumtoxin A in der Ästhetischen Dermatologie. Kosmetische Medizin. 2003;24:2-8.
12. Rzany B, Fratila A, Heckmann M. 2. Expertentreffen zur Anwendung von Botulinumtoxin A (Dysport® ) in der Ästhetischen Dermatologie. Kosmetische Medizin 2005;26:134-141.
13. Carruthers J, Fagien S, Matarasso SL; Botox Consensus Group. Consensus recommendations on the use of botulinum toxin type a in facial aesthetics. Plast Reconstr Surg. 2004;114(6 Suppl):1S- 22S.
14. Klein AW. The art and science of treating facial wrinkles with botulinum toxin A. J Am Acad Dermatol. 2005;53:364-365. (Pubitemid 40979611)
15. Flynn TC, Carruthers A, Carruthers J. Surgical pearl: The use of the Ultra-Fine II short needle 0.3-cc insulin syringe for botulinum toxin injections. J Am Acad Dermatol. 2002;46:931-933.
16. Ascher B, Zakine B, Kestemont P, et al. A multicenter, randomized, double-blind, placebo-controlled study of efficacy and safety of three doses of botulinum toxin A in the treatment of glabellar lines. J Am Acad Dermatol. 2004;51:223-233.
17. Ascher B, Zakine B, Kestemont P, et al. Botulinum toxin A in the treatment of glabellar lines: Scheduling the next injection. Aesthet Surg J. 2005;25:365-375. (Pubitemid 41093742)
18. Rzany B, Ascher B, Fratila A, et al. Efficacy and safety of 3- and 5-injection patterns (30 and 50 U) of botulinum toxin A (Dysport) for the treatment of wrinkles in the glabella and the central forehead region. Arch Dermatol. 2006;142:320-326.
19. Monheit G, Carruthers A, Brandt F, Rand R. A randomized, doubleblind, placebo-controlled study of botulinum toxin type A for the treatment of glabellar lines: determination of optimal dose. Dermatol Surg. 2007;33(1 Spec No.):S51-S59. (Pubitemid 46051400)
20. Brandt F, Swanson N, Baumann L, Huber B. Randomized, placebocontrolled study of a new botulinum toxin type A for treatment of glabellar lines: efficacy and safety. Dermatol Surg. 2009, Jun 22. [Epub ahead of print].
21. Kane MA, Brandt F, Rohhrich RJ, et al. Evaluation of variable-dose treatment with a new U.S. botulinum toxin type A (Dysport) for correction of moderate to severe glabellar lines: results from a phase 3, randomized, double-blind, placebo-controlled study. Plast Reconstr Surg. 2009, Jul 28. [Epub ahead of print]
22. Rubin MG, Dover J, Glogau RG, et al. The efficacy and safety of a new U.S. Botulinum toxin type A in the retreatment of glabellar lines following open-label treatment. J Drugs Dermatol. 2009;8:439-444.
23. Moy R, Maas C, Monheit G, et al. Long-term safety and efficacy of a new botulinum toxin type A in treating glabellar lines. Arch Facial Plast Surg. 2009;11:77-83.
24. Monheit GD, Cohen JL; the Reloxin Investigational Group. Longterm safety of repeated administrations of a new formulation of botulinum toxin type A in the treatment of glabellar lines: Interim analysis from an open-label extension study. J Am Acad Dermatol. 2009;61:421-425.
25. Rzany B, Dill-Müller D, Grablowitz D, et al. Repeated botulinum toxin A injections for the treatment of lines in the upper face: A retrospective study of 4,103 treatments in 945 patients. Dermatol Surg. 2007;33(1 Spec No.):S18-S25. (Pubitemid 46051395)
26. Carruthers A, Carruthers J, Lowe NJ, et al. One-year, randomized, multicenter, two-period study of the safety and efficacy of repeated treatments of botulinum toxin type A in patients with glabellar lines. J Clin Res. 2004;7:1-20. (Pubitemid 38843595)
27. Carruthers A, Carruthers J. Prospective, double-blind, randomized, parallel-group, dose-ranging study of botulinum toxin type A in men with glabellar rhytids. Dermatol Surg. 2005;31:1297-1303. (Pubitemid 41587037)
28. Carruthers A, Carruthers J, Said S. Dose-ranging study of botuli- num toxin type A in the treatment of glabellar rhytids in females. Dermatol Surg. 2005;31:414-422. (Pubitemid 40489301)
29. Flynn TC. Botox in men. Dermatol Ther. 2007; 20:407-413. (Pubitemid 350265329)
30. Dysport (abobotulinumtoxinA) [package insert]. Brisbane, California and Scottsdale, AZ; Tercica, Inc., a subsidiary of the Ipsen Group and Medicis Aesthetics Inc.; April 29, 2009.
31. Carruthers JA, Lowe NJ, Menter MA, et al. A multicenter, doubleblind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines. J Am Acad Dermatol. 2002;46:840-849.
32. Carruthers JD, Lowe NJ, Menter MA, et al. Double-blind, placebo- controlled study of the safety and efficacy of botulinum toxin type A for patients with glabellar lines. Plast Reconstr Surg. 2003;112:1089-1098. (Pubitemid 38251807)
33. Ascher B, Rossi B. Chapter 15. Optimal dosing and side-effects. In: Ascher B, Landau M, Rossi B, eds. Injection treatments in cosmetic surgery. London: Informa UK Ltd; 2009:115-124.
34. Wohlfarth K, Sycha T, Ranoux D, et al. Dose equivalence of two commercial preparations of botulinum neurotoxin type A: time for a reassessment? Curr Med Res Opin. 2009;25:1573-1584.
35. Carli L, Montecucco C, Rossetto O. Assay of diffusion of different botulinum neurotoxin type a formulations injected in the mouse leg. Muscle Nerve. 2009;40:374-380.
36. Ranoux D, Gury C, Fondarai J, et al. Respective potencies of Botox and Dysport: a double blind, randomised, crossover study in cervical dystonia. J Neurol Neurosurg Psychiatry. 2002;72:459-462.
37. Marchetti A, Magar R, Findley L, et al. Retrospective evaluation of the dose of Dysport and BOTOX in the management of cervical dystonia and blepharospasm: the REAL DOSE study. Mov Disord. 2005;20:937-944. (Pubitemid 41419507)
38. Karsai S, Raulin C. Current evidence on the unit equivalence of different botulinum neurotoxin A formulations and recommendations for clinical practice in dermatology. Dermatol Surg. 2009;35(1):1-8.
39. Sampaio C, Costa J, Ferreira JJ. Clinical comparability of marketed formulations of botulinum toxin. Mov Disord. 2004;19 (Suppl 8):S129-S136. (Pubitemid 38967522)
40. FDA requires boxed warning for all botulinum toxin products. April 30, 2009; FDA News Release. Available at : http://www.fda.fov/ newsevents/newsroom/ pressannouncements/ucm149574.htm. Accessed May 31, 2009.
41. Aoki KR, Ranoux D, Wissel J. Using translational medicine to understand clinical differences between botulinum toxin formulations. Eur J Neurol. 2006;13 Suppl 4:10-19. (Pubitemid 44748279)
42. Pickett A, Dodd S, Rzany B. Confusion about diffusion and the art of misinterpreting data when comparing different botulinum toxins used in aesthetic applications. J Cosmet Laser Ther. 2008;10:181-183.
43. Cliff SH, Judodihardjo H, Eltringham E. Different formulations of botulinum toxin type A have different migration characteristics: a double-blind, randomized study. J Cosmet Dermatol. 2008;7:50-54. (Pubitemid 351228167)
44. Trindade de Almeida AR, Marques E, de Almeida J, et al. Pilot study comparing the diffusion of two formulations of botulinum toxin type A in patients with forehead hyperhidrosis. Dermatol Surg. 2007;33(1 Spec No.):S37-S43. (Pubitemid 46051398)
45. Hexsel D, Dal'Forno T, Hexsel C, et al. A randomized pilot study comparing the action halos of two commercial preparations of botulinum toxin type A. Dermatol Surg. 2008;34:52-59. (Pubitemid 350308586)
46. Heckmann M, Schön-Hupka G. Quantification of the efficacy of botulinum toxin type A by digital image analysis. J Am Acad Dermatol. 2001;45:508-514. (Pubitemid 32917243)
47. Flynn TC, Clark RE 2nd. Botulinum toxin type B (MYOBLOC) versus botulinum toxin type A (BOTOX) frontalis study: Rate of onset and radius of diffusion. Dermatol Surg. 2003;29:519-522. (Pubitemid 36583151)
48. Boyle MH, McGwin G Jr, Flanagan CE, et al. High versus low concentration botulinum toxin A for benign essential blepharospasm: Does dilution make a difference? Ophthal Plast Reconstr Surg. 2009;25:81-84.
49. Carruthers A, Carruthers J, Cohen J. Dilution volume of botulinum toxin type A for the treatment of glabellar rhytides: Does it matter? Dermatol Surg. 2007;33(1 Spec No.):S97-S104. (Pubitemid 46051407)
50. Carruthers A, Bogle M, Carruthers JD, et al. A randomized, evaluator- blinded, two-center study of the safety and effect of volume on the diffusion and efficacy of botulinum toxin type A in the treatment of lateral orbital rhytides. Dermatol Surg. 2007;33:567-571. (Pubitemid 46650366)
51. Alam M, Yoo SS, Wrone DA, et al. Sterility assessment of multiple use botulinum A exotoxin vials: a prospective simulation. J Am Acad Dermatol. 2006;55:272-275. (Pubitemid 44038009)
52. Gartlan MG, Hoffman HT. Crystalline preparation of botulinum toxin type A (Botox): degradation in potency with storage. Otolaryngol Head Neck Surg. 1993;108:135-140. (Pubitemid 23086689)
53. Hexsel D, Rutowitsch MS, de Castro LC, et al. Blind multicenter study of the efficacy and safety of injections of a commercial preparation of botulinum toxin type A reconstituted up to 15 days before injection. Dermatol Surg. 2009;35:933-939.
54. Hui JI, Lee WW. Efficacy of fresh versus refrigerated botulinum toxin in the treatment of lateral periorbital rhytids. Ophthal Plast Reconstr Surg. 2007;23:433-438. (Pubitemid 350146480)
55. Hexsel DM, De Almeida AT, Rutowitsch M, et al. Multicenter, double- blind study of the efficacy of injections with botulinum toxin type A reconstituted up to six consecutive weeks before application. Dermatol Surg. 2003;29:523-529. (Pubitemid 36583152)
56. Parsa AA, Lye KD, Parsa FD. Reconstituted botulinum type A neurotoxin: clinical efficacy after long-term freezing before use. Aesthetic Plast Surg. 2007;31:188-191. (Pubitemid 46625386)
57. Yang GC, Chiu RJ, Gillman GS. Questioning the need to use Botox within 4 hours of reconstitution: A study of fresh vs 2-week-old Botox. Arch Facial Plast Surg. 2008;10:273-279.
58. Thomas JP, Siupsinskiene N. Frozen versus fresh reconstituted botox for laryngeal dystonia. Otolaryngol Head Neck Surg. 2006;135:204-208. (Pubitemid 44142147)
59. Sloop RR, Cole BA, Escutin RO. Reconstituted botulinum toxin type A does not lose potency in humans if it is refrozen or refrigerated for 2 weeks before use. Neurology. 1997;48:249-253. (Pubitemid 27039549)
60. de Maio M, Rzany B. Botulinum Toxin in Aesthetic Medicine. Heidelberg: Springer-Verlag; 2007.
61. Carruthers J, Carruthers A. Botulinum toxin A in the mid and lower face and neck. Dermatol Clin. 2004;22:151-158. (Pubitemid 38638568)